Literature DB >> 1397723

1,25-Dihydroxyvitamin D3 prevents insulitis in NOD mice.

C Mathieu1, J Laureys, H Sobis, M Vandeputte, M Waer, R Bouillon.   

Abstract

The active form of vitamin D, 1,25(OH)2D3, can prevent various forms of experimentally induced autoimmune disorders. The aim of this study was to confirm these findings in NOD mice that spontaneously develop an autoimmune type of diabetes mellitus. Therefore, the effect of a long-term 1,25(OH)2D3 treatment on the incidence of insulitis, the histological lesion preceding diabetes, was studied. Forty-three NOD mice were treated with 1,25(OH)2D3 (5 micrograms/kg) i.p. every other day from age 21 days on, when no insulitis was present yet. At day 100, 16 control mice receiving the treatment vehicle (arachis oil) had an incidence of insulitis of 75%, whereas only 41% of the 1,25(OH)2D3-treated animals developed insulitis (P < 0.025). Calcemia, determined 24 h after the last 1,25(OH)2D3 injection was 2.5 +/- 0.1 mM, which was higher than in control animals (2.3 +/- 0.1 mM), but was well tolerated. Cellular immunity, as assessed with the mixed lymphocyte reaction performed at day 100, was not impaired significantly. This study demonstrates that long-term treatment with high doses of 1,25(OH)2D3 is able to decrease the incidence of insulitis in spontaneous autoimmune diabetes without major side effects.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1397723     DOI: 10.2337/diab.41.11.1491

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  42 in total

Review 1.  Immunotherapy of immune-mediated diabetes. Present and future.

Authors:  N Maclaren
Journal:  Clin Rev Allergy Immunol       Date:  2000-12       Impact factor: 8.667

2.  Vitamin D and autoimmune thyroid diseases.

Authors:  Shaye Kivity; Nancy Agmon-Levin; Michael Zisappl; Yinon Shapira; Endre V Nagy; Katalin Dankó; Zoltan Szekanecz; Pnina Langevitz; Yehuda Shoenfeld
Journal:  Cell Mol Immunol       Date:  2011-01-31       Impact factor: 11.530

3.  The use of real-time reverse transcriptase PCR for the quantification of cytokine gene expression.

Authors:  L Overbergh; A Giulietti; D Valckx; R Decallonne; R Bouillon; C Mathieu
Journal:  J Biomol Tech       Date:  2003-03

4.  Calcium insufficiency accelerates type 1 diabetes in vitamin D receptor-deficient nonobese diabetic (NOD) mice.

Authors:  John P Driver; Deanna J Lamont; Conny Gysemans; Chantal Mathieu; David V Serreze
Journal:  Endocrinology       Date:  2011-09-27       Impact factor: 4.736

5.  Genes mediating environment interactions in type 1 diabetes.

Authors:  Erik Biros; Margaret A Jordan; Alan G Baxter
Journal:  Rev Diabet Stud       Date:  2006-02-10

6.  Lineage-specific effects of 1,25-dihydroxyvitamin D(3) on the development of effector CD4 T cells.

Authors:  Matthew T Palmer; Yun Kyung Lee; Craig L Maynard; James R Oliver; Daniel D Bikle; Anton M Jetten; Casey T Weaver
Journal:  J Biol Chem       Date:  2010-11-03       Impact factor: 5.157

Review 7.  Metabolites: deciphering the molecular language between DCs and their environment.

Authors:  Lucía Minarrieta; Peyman Ghorbani; Tim Sparwasser; Luciana Berod
Journal:  Semin Immunopathol       Date:  2016-12-05       Impact factor: 9.623

8.  Comparative therapeutic effects of orally administered 1,25-dihydroxyvitamin D(3) and 1alpha-hydroxyvitamin D(3) on type-1 diabetes in non-obese diabetic mice fed a normal-calcaemic diet.

Authors:  J P Driver; O Foreman; C Mathieu; E van Etten; D V Serreze
Journal:  Clin Exp Immunol       Date:  2007-11-05       Impact factor: 4.330

9.  Treating tumor-bearing mice with vitamin D3 diminishes tumor-induced myelopoiesis and associated immunosuppression, and reduces tumor metastasis and recurrence.

Authors:  M R Young; J Ihm; Y Lozano; M A Wright; M M Prechel
Journal:  Cancer Immunol Immunother       Date:  1995-07       Impact factor: 6.968

10.  Interaction of vitamin D receptor with HLA DRB1 0301 in type 1 diabetes patients from North India.

Authors:  Neetu Israni; Ravinder Goswami; Avinash Kumar; Rajni Rani
Journal:  PLoS One       Date:  2009-12-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.